Evidence map›Paper›PMID 40775713›Full record

ArticleJournal of nanobiotechnology2025

Pre-formation loading of extracellular vesicles with exogenous molecules using photoporation.

Jana Ramon, Cláudio Pinheiro, Charysse Vandendriessche, Estefanía Lozano-Andrés, Herlinde De Keersmaecker, Deep Punj, Juan C Fraire, Edward Geeurickx, Marca H M Wauben, Pieter Vader and 6 more

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jana RamonLaboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Cláudio PinheiroCancer Research Institute Ghent (CRIG), Ghent, Belgium.
Charysse VandendriesscheVIB Center for Inflammation Research, Ghent, Belgium.
Estefanía Lozano-AndrésDepartment of Biomolecular Health Sciences, Faculty of Veterinary Sciences, Utrecht University, Utrecht, The Netherlands.
Herlinde De KeersmaeckerLaboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Deep PunjLaboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Juan C FraireLaboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Edward GeeurickxLaboratory of Experimental Cancer Research, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Marca H M WaubenDepartment of Biomolecular Health Sciences, Faculty of Veterinary Sciences, Utrecht University, Utrecht, The Netherlands.
Pieter VaderCDL Research, University Medical Center Utrecht, Utrecht, The Netherlands.
Roosmarijn E VandenbrouckeCancer Research Institute Ghent (CRIG), Ghent, Belgium.
An HendrixCancer Research Institute Ghent (CRIG), Ghent, Belgium.
Stephan StremerschLaboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Stefaan C De SmedtLaboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Koen RaemdonckLaboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Kevin BraeckmansLaboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. Kevin.Braeckmans@UGent.be.

Funding

Bijzonder Onderzoeksfonds UGent BOF21/GOA/031Bijzonder Onderzoeksfonds UGent BOF.COR.2022.0003.01Departament d'Empresa i Coneixement, Generalitat de Catalunya 2021-BP-00079Fonds Wetenschappelijk Onderzoek 1110721NFonds Wetenschappelijk Onderzoek 1295223NFonds Wetenschappelijk Onderzoek 12AZ724NFonds Wetenschappelijk Onderzoek I000321NFonds Wetenschappelijk Onderzoek S006319NH2020 European Research Council 648124HORIZON EUROPE Marie Sklodowska-Curie Actions 722148Ministerio de Ciencia e Innovación RYC2023-043053-I
6 · The paper itself

Abstract

Despite the natural capacity of extracellular vesicles (EVs) to encapsulate intracellular compounds and transfer these to nearby or distant recipient cells, the intentional loading of EVs with cargo molecules remains a challenging endeavor. Pre-formation EV loading (i.e., during EV biogenesis), offers advantages compared to post-formation loading (i.e., after EV isolation), as EV integrity and composition are minimally perturbed. Pre-formation EV loading is primarily achieved through the genetic engineering of the producer cell, which is time consuming and not very flexible regarding the types of molecules that can be incorporated into EVs. In this work, we investigated the possibility of loading cargo molecules into EVs by delivering the cargo directly into the cytosol of the producer cells, which can subsequently be encapsulated into EVs as they are formed. For the cytosolic delivery of cargo molecules, we evaluated the use of photoporation. This membrane disruption technology has been demonstrated to successfully deliver a broad range of cargo molecules into virtually any cell type, while minimally impacting the cell's normal functioning and homeostasis. As a proof-of-concept, we delivered fluorescently labeled dextran macromolecules and anti-EGFP nanobodies into HEK293T cells genetically engineered with gag-EGFP fusion proteins, which are shuttled into EVs. Colocalization of cargo and EGFP fluorescence in secreted EVs can then serve as a convenient readout for successful EV loading. We established that photoporation had minimal impact on EV characteristics such as concentration, size, zeta potential and the enrichment of EV tetraspanin membrane surface molecules. We found that using EGFP-targeted nanobodies resulted in up to 53% loaded EVs (relative to the amount of EGFP EVs), while non-targeted dextran molecules produced on average 12% loaded EVs (relative to the amount of EGFP EVs). These results highlight the promise of photoporation for pre-formation loading of EVs.

Indexed as

Extracellular VesiclesCytosolDextransGreen Fluorescent ProteinsHEK293 CellsHumansDextransenhanced green fluorescent proteinGreen Fluorescent Proteins

Identifiers

PMID40775713
PMCPMC12333136

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.